|
|
|
Volumn 26, Issue 3 SUPPL. 8, 1999, Pages 14-20
|
|
Single-agent paclitaxel in the treatment of breast cancer: Phase I and II development
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER ANTIBODY;
PACLITAXEL;
TAXANE DERIVATIVE;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BONE MARROW SUPPRESSION;
BREAST CARCINOMA;
CANCER CHEMOTHERAPY;
CANCER RESISTANCE;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG HYPERSENSITIVITY;
HUMAN;
MUCOSA INFLAMMATION;
NEUROTOXICITY;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
|
|
EID: 0033004830
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (24)
|
|
References (53)
|
